Mitsubishi UFJ Trust & Banking’s Recursion Pharmaceuticals RXRX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-908,455	Closed	-$2.79M	–	1577
2026 Q1	$2.79M	Buy	+908,455	New	+$3.51M	0.01%	735
2024 Q3	–	Sell	-240,720	Closed	-$1.81M	–	1115
2024 Q2	$1.81M	Sell	240,720 -29,640	-11%	-$259K	﹤0.01%	801
2024 Q1	$2.7M	Sell	270,360 -31,130	-10%	-$347K	0.01%	755
2023 Q4	$2.97M	Sell	301,490 -47,980	-14%	-$342K	0.01%	738
2023 Q3	$2.67M	Sell	349,470 -9,060	-3%	-$90.4K	0.01%	752
2023 Q2	$2.68M	Sell	358,530 -8,860	-2%	-$62K	0.01%	758
2023 Q1	$2.45M	Hold	367,390	–	–	0.01%	753
2022 Q4	$2.83M	Hold	367,390	–	–	0.01%	742
2022 Q3	$3.91M	Sell	367,390 -6,000	-2%	-$60.8K	0.01%	700
2022 Q2	$3.04M	Hold	373,390	–	–	0.01%	743
2022 Q1	$2.67M	Hold	373,390	–	–	0.01%	773
2021 Q4	$6.4M	Sell	373,390 -25,030	-6%	-$471K	0.01%	697
2021 Q3	$9.17M	Buy	+398,420	New	+$11.3M	0.02%	626

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's RXRX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 908,455 shares — an estimated $2.79M sold.

Mitsubishi UFJ Trust & Banking first reported a position in RXRX in Q3 2021 and held it in 13 quarters. The position peaked at $9.17M in Q3 2021. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Mitsubishi UFJ Trust & Banking reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Mitsubishi UFJ Trust & Banking sold 908,455 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.79M.
Mitsubishi UFJ Trust & Banking first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 13 quarters.
Mitsubishi UFJ Trust & Banking's Recursion Pharmaceuticals position peaked at $9.17M in Q3 2021.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.